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statins have been widely investigated, and their use is usually
recommended in the secondary prevention of acute coronary
syndrome (ACS). To investigate the use of statins for the
primary prevention of ACS, between April 2004 and February
2005 we enrolled a total of 31 end-stage renal disease patients
on MHD, with neither history nor clinical and instrumental
signs of earlier major adverse cardiac events (MACEs). We
started each patient on atorvastatin (10 mg) daily regardless
of serum low-density lipoprotein cholesterol associated with
conventional pharmacologic control of blood pressure, serum
glucose, and calcium–phosphate balance. During a 4-year
follow-up overall 3-year actuarial survival was 67%,3
compared with a 20–40% 5-year survival reported earlier.4
Cardiovascular mortality was 12.9%, (4 patients). ‘MACE’
free’ (lethal and non-lethal) 3-year actuarial survival was
53%. Treatment with statins may be considered in the
primary prevention of MACEs in hemodialysis patients.
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Considering the clinical benefits of statins for primary
and secondary cardiovascular event prevention in normal
renal function patients, one can assume a similar benefit
for patients with chronic kidney disease. Accordingly,
Manca-di-Villahermosa’s letter1 reports that a small group
of end-stage renal disease patients receiving atorvastatin
show low cardiovascular mortality after 3 years of follow-
up. However, in the 4-D study—the only randomized
placebo-controlled statin trial done to date, which
included 1255 patients with type 2 diabetes undergoing
hemodialysis—atorvastatin administration was not
associated with cardiovascular mortality reduction, which
accounts for half the deaths in such patients.2 Moreover,
this occurs independently of the presence or absence of
high c-reactive protein levels that are associated with
cardiovascular event risk.3 Reasons for this discrepancy are
not evident, as statins exert anti-inflammatory, antiox-
idant, and lipid-lowering effects as effective as those
observed in normal renal function participants. End-stage
renal disease patients are at high risk for cardiovascular
complications, in whom cardiovascular disease is con-
sidered complex and aggravated by coexisting factors,
including malnutrition, accelerated atherosclerosis, left
ventricular hypertrophy, cardiac fibrosis, and sympathetic
overactivity. In the 4-D study, most of cardiovascular
deaths were caused by sudden death and not by coronary
heart disease.2 Data for two ongoing large trials (AURORA
and SHARP) would help put into perspective statin’s
beneficial effect in chronic kidney disease with respect to
cardiovascular mortality. Apart from this, it has been
reported that statin use is associated with sepsis incidence
reduction—a major cause of morbimortality in chronic
kidney disease.4 This protective benefit could contribute to
total mortality reduction in peritoneal dialysis and
hemodialysis patients using statins reported by some
observational studies (e.g., DOPPS).5
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To the Editor: Phosphonoformic acid (PFA) is a non-
hydrolyzeable inorganic pyrophosphate analog, and it
has been used as an experimental inhibitor of renal and
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intestinal inorganic phosphate (Pi) transport.1 PFA com-
petitively inhibits type II Na/Pi cotransporters (intestinal
NaPi-IIb, and renal NaPi-IIa and NaPi-IIc).1 Conversely, it is
not an inhibitor of type III Pi transporters, namely the
ubiquitous Pit-1 and Pit-2, as we have shown2 and as Professor
Giachelli has demonstrated recently in this journal.3
PFA successfully prevents Pi-induced calcification of
vascular smooth muscle cells (VSMCs; EC50 of 60 mM),
4,
but it inhibits Pi transport with very low affinity (Ki 2.6 mM)
2
because these cells only express type III Na/Pi cotranspor-
ters.2 Therefore, the mechanism of vascular prevention by
PFA should be different from that of Pi-transport inhibition,
as we have described recently (Figure 1).
In a recent study,4 we clarified the mechanism whereby
PFA prevents VSMC calcification. We showed that PFA
inhibits calcium-phosphate deposition in a process that is
independent of any cell activity or metabolism and that is
similar to the physicochemical mechanism of bisphosphonate
drugs and pyrophosphate.4 This rationale was already
proposed decades ago by several researchers, and it also
coincides with a recent study by Prof. O’Neill’s group.5
Therefore, the use of PFA as a tool to inhibit Pi transport in
vascular calcification research should be avoided, because the
concentrations of PFA that significantly inhibit Pi transport
in VSMC also exhibit cytotoxic side effects.4
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Despite the fact that phosphonoformic acid (PFA) is a very
weak inhibitor of the type III phosphate transporters
present in vascular smooth muscle, its inhibition of
calcification in cultured vascular smooth muscle cells
(VSMCs) has been used to support a role for phosphate
transport in vascular calcification.1 However, as pointed
out by Villa-Bellosta and Sorribas,2 PFA is also a non-
hydrolyzable analog of pyrophosphate (PPi). PPi is a
potent, direct inhibitor of hydroxyapatite crystal forma-
tion that inhibits vascular calcification in vitro and in vivo,
a property shared by a number of analogs, including
bisphosphonates.3 Not surprisingly, Villa-Bellosta and
Sorribas have shown that this is also the mechanism by
which PFA inhibits calcification in VSMCs. This is yet
another example of a ‘specific’ inhibitor that, like most
‘specific’ inhibitors, is not specific.
Subsequent studies using antisense RNA directed
against Pit-1 have also shown inhibition of calcification
in VSMCs,4 supporting a role for phosphate transport.
However, caution must also be exercised in interpreting
these results because VSMCs undergo substantial pheno-
typic changes in culture and lack the normal elastin
matrix, which is the site of medial calcification in vivo.
Using the whole aorta culture method, we have been
unable to duplicate many of the findings in VSMCs related
to medial calcification. Thus, the intriguing and potentially
important role of phosphate transporters in vascular
calcification, although widely cited, remains to be proven
in a relevant model.
1. Jono S, McKee MD, Murry CE et al. Phosphate regulation of vascular
smooth muscle cell calcification. Circ Res 2000; 87: E10–E17.
2. Villa-Bellosta R, Sorribas V. On the vascular calcification prevention
with phosphonoformate and bisphosphonates. Kidney Int 2009; 75:
1355–1356.
3. Lomashvili KA, Monier-Faugere MC, Wang X et al. Effect of
bisphosphonates on vascular calcification and bone metabolism in
experimental renal failure. Kidney Int 2009; 75: 617–625.
4. Li X, Yang HY, Giachelli CM. Role of the sodium-dependent phosphate
cotransporter, Pit-1, in vascular smooth muscle cell calcification. Circ Res
2006; 98: 905–912.
Koba A. Lomashvili1 and W. Charles O’Neill1
1Emory University, Renal Division, WMB 338, Atlanta, Georgia, USA
Correspondence: W. Charles O’Neill, Emory University, Renal Division, WMB
338, 1639 Pierce Dr, Atlanta, GA 30322, USA.
E-mail: woneill@emory.edu
%
 o
f c
on
tro
l
Ki
PFA 
≈ 2.7 mM
110
100
90
80
70
60
50
40
30
20
10
0
–3.0 –2.5 –2.0 –1.5 –1.0 –0.5 0.0
log[PFA], mM
Calcium deposition
Phosphate uptake
Km
Pi
 ≈ 100 µM
EC50
PFA
 ≈ 60 µM
Figure 1 | Effect of phosphonoformic acid (PFA) on inorganic
phosphate (Pi) transport and calcium deposition in vascular
smooth muscle cells.
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